Literature DB >> 9571511

Efficacy of ultrasonic mass survey for abdominal cancer.

S Mihara1, K Nagano, K Kuroda, R Yoshioka, M Sawatari, H Koba, S Tanaka, S Hirao, M Machihara, K Hondou, E Morimoto, W Koyama.   

Abstract

From August 1983 through March 1995, 204,099 people received ultrasonic mass survey of the abdomen for the first time. Among these examinees, 631 (0.31%) malignant neoplasm cases, such as 201 hepatocellular carcinoma (HCC), 81 gallbladder (GB) cancer, 57 pancreatic cancer, and 169 renal cell carcinoma (RCC), were detected. Three hundred seventy six out of 590 cases (64%), excluding chronic leukemia cases and metastatic liver cancer cases, were surgically resected. The resection rate of HCC, GB cancer, pancreatic cancer, and RCC were 25%, 88%, 49%, and 99%, respectively. The cumulative survival rate of the 376 resected cases was 79.5% at 10 years. The cumulative survival rates of resected cases of HCC, GB cancer, pancreatic cancer and cumulative survival rates of resected cases of HCC, GB cancer, pancreatic cancer and RCC were 34% at ten years, 83% at 10 years, 49% at 7 years, and 99% at 10 years, respectively. Ultrasonic mass survey is dramatically useful for early detection of various kinds of abdominal cancers, especially RCC and GB cancer. From now on, many earlier abdominal cancers will be found by establishing and promoting ultrasonic mass survey systems.

Entities:  

Mesh:

Year:  1998        PMID: 9571511     DOI: 10.1023/a:1022634900391

Source DB:  PubMed          Journal:  J Med Syst        ISSN: 0148-5598            Impact factor:   4.460


  1 in total

1.  Incidence and properties of renal masses and asymptomatic renal cell carcinoma detected by abdominal ultrasonography.

Authors:  A Tosaka; K Ohya; K Yamada; H Ohashi; S Kitahara; H Sekine; Y Takehara; K Oka
Journal:  J Urol       Date:  1990-11       Impact factor: 7.450

  1 in total
  1 in total

Review 1.  How Can We Manage Gallbladder Lesions by Transabdominal Ultrasound?

Authors:  Shinji Okaniwa
Journal:  Diagnostics (Basel)       Date:  2021-04-26
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.